Detalhe da pesquisa
1.
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.
Eur J Cancer
; 160: 1-11, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34801354
2.
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma.
J Immunother Cancer
; 8(2)2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33361337
3.
Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy.
Int J Radiat Oncol Biol Phys
; 73(3): 818-23, 2009 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18718726